Prognostic Significance of Exposure to Intermediate-Dose Methotrexate in Children with Standard Risk ALL: The COALL 82/85 Experience
Authors:
- 1 January 1992
- book chapter
- Published by Springer Nature
- p. 338-342
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Rescue after Intermediate and High-Dose Methotrexate: Background, Rationale, and Current PracticePediatric Hematology and Oncology, 1990
- New vistas for leucovorin in cancer chemotherapyCancer, 1989
- Systemic clearance of methotrexate in the prognosis of acute lymphoblastic leukemia in childrenCancer, 1987
- Akute lymphoblastische Leukämie im Kindesalter: Die COALL-Studien*Klinische Padiatrie, 1986
- Intermediate-dose methotrexate in the treatment of childhood acute lymphocytic leukaemia: lack of benefit during maintenance therapy following intensive induction therapyEuropean Journal of Pediatrics, 1986
- METHOTREXATE SYSTEMIC CLEARANCE INFLUENCES PROBABILITY OF RELAPSE IN CHILDREN WITH STANDARD-RISK ACUTE LYMPHOCYTIC LEUKAEMIAThe Lancet, 1984
- Prolonged Methotrexate Infusions in Children with Acute Leukemia in Relapse and in Remission and with MedulloblastomaOncology, 1984
- INTERMEDIATE DOSE METHOTREXATE (IDM) IN CHILDHOOD ACUTE LYMPHOCYTIC LEUKEMIA IN NORWAYActa Paediatrica, 1981
- Intermediate Dose Methotrexate (IDM) in Childhood Acute Lymphocytic Leukemia (ALL)1979
- The clinical pharmacology of methotrexate.new applications of an old drugCancer, 1978